BAP1 and uveal melanoma: Figueiredo et al. recently demonstrated BAP1-deficient uveal melanomas exhibit an immunosuppressive environment, with upregulation of regulatory T-cells leading to inhibition of cytotoxic T-cells and proposed anti-CD38/anti-CD74 compounds could be used in combination with ICI to increase the response rates to therapy [18].